House Appropriators Ask Feds to Use “Any Available Measures” to Curb Pharma’s 340B Pricing Denials

U.S. House Appropriations Committee room
The U.S. House Appropriations Committee says HRSA should use "any available means" to hold drug makers accountable for curtailing "use of 340B drugs in contract pharmacies."

The U.S. House Appropriations Committee said this week it is concerned about the growing number of drug manufacturers “that curtail the use of 340B drugs in contract pharmacies.” It encouraged the U.S. Health Resources and Services Administration to use “any

Read More »

As UCB Reviews HRSA’s 340B Enforcement Letter, Grassley Presses OIG for Answers

Sen. Chuck Grassley (R-IA) speaking in a meeting with hospital employees
U.S. Sen. Chuck Grassley (R-Iowa), after meeting with 340B hospital employees in his home state, tweeted that he needs answers about drug company 340B violations and actions HHS may take.

Drug manufacturer UCB says it is reviewing Monday’s letter from the U.S. Health Resources and Services Administration telling the company its restrictions on 340B pricing to covered entities that use contract pharmacies break federal law and must end immediately.

“At

Read More »

Sponsor Halts California Bill to Shield 340B Providers from Manufacturers and PBMs’ Actions

California State Sen. Richard Pan (D) speaking to a large assembly
California state Sen. Richard Pan (D) asked a state Assembly committee to cancel a hearing on his Senate-approved bill to prohibit drug manufacturer conditions on 340B pricing and pharmacy benefit manager discrimination against 340B covered entities.

A bill in California to prohibit drug manufacturer conditions on 340B pricing and pharmacy benefit manager discrimination against 340B covered entities died in a state Assembly committee on Tuesday.

The state Senate voted 24-9 to pass the bill, SB-939, on

Read More »

AHA Tells HHS It Wants Prompt Repayment for All Years Hospitals’ Medicare Drug Payments Have Been Cut

American Hospital Association seal on interior office wall
The American Hospital Association and other major hospital groups have placed multiple 340B program goals on their 2024 advocacy agendas.

The American Hospital Association wants to discuss with U.S. Health and Human Services Secretary Xavier Becerra how 340B hospitals should be promptly repaid “for all of the years (2018-2022) in which the Centers for Medicare & Medicaid Services (CMS) illegally

Read More »

Q3 340B Entity Registration Starts Tomorrow

Screenshot of HRSA Office of Pharmacy Affairs 340B registration page
The Q3 2022 registration period for healthcare providers, outpatient facilities, and contract pharmacies to participate in 340B begins July 1 and ends July 15.

The third quarterly period this year for 340B registration of new covered entities, outpatient facilities, and contract pharmacies will begin tomorrow, July 1, and end on Friday, July 15.

Eligible hospitals, health centers, clinics, and their child sites and contract

Read More »

340B PROVIDER LEADER SPOTLIGHT

Jessica Rivas, Chief Pharmacy Officer for Big Bend Cares and Scholarship Recipient for the Apexus Advanced 340B Operations Certificate Program

Jessica Rivas headshot
Jessica Rivas

Q: Where did you complete your professional training?

I completed my pharmacy technician program during my senior year in high school at Westside Tech in Orlando, Florida. I am

Read More »

HRSA Tells UCB its 340B Contract Pharmacy Policy Is Illegal

UCB exterior sign and building
Drugmaker UCB recently told 340B providers in Arkansas that it will exempt them from its contract pharmacy restrictions.

Federal healthcare officials told drug manufacturer UCB yesterday its restrictions on 340B pricing when covered entities use contract pharmacies are illegal and must stop or the company could face civil monetary penalties of up to $6,323.00 for each instance of

Read More »

Feds Ask Appeals Court to Partially Reverse Ruling on Lilly’s 340B Contract Pharmacy Policy

Lilly corporate center exterior sign
The federal government asked an appeals court to affirm one part and vacate another of a lower court's opinion about the legality of Lilly's 340B contract pharmacy restrictions.

A federal district judge was right to decide that drug manufacturer Lilly cannot tie strings to 340B pricing on its drugs, the U.S. Justice Department told a federal appeals court in Chicago on Friday. But, DOJ said, the judge was

Read More »

Clinics Pay Gilead $33 Million to Settle Fraud Claims Involving 340B-Related PrEP Transactions

Truvada open pill bottle and pills
A group of Florida healthcare providers will pay $33 million to settle Gilead's claims the group made fraudulent 340B-related transactions involving the company’s HIV pre-exposure prophylaxis drugs.

One of two groups of Florida health care providers that drug maker Gilead accused of making fraudulent 340B-related transactions involving the company’s HIV pre-exposure prophylaxis drugs agreed last week to settle Gilead’s claims against it for $33 million.

A mediation

Read More »

Supreme Court DSH Calculation Ruling Leaves 340B Status Quo in Place, Experts Say

U.S. Supreme Court building
A U.S. Supreme Court decision about the Medicare DSH adjustment percentage calculation is expected to have little effect on hospitals currently in the 340B drug pricing program.

A U.S. Supreme Court decision last week about the Medicare disproportionate share adjustment percentage calculation will have little effect on hospitals currently in the 340B drug pricing program, experts say. It could mean, though, that some on the cusp of

Read More »